Atherosclerotic renal artery stenosis (ARAS) represents 1% to 2% of all cases of secondary
hypertension in the general population, rising up to 5.8%in patients ≥65 years old
[
[1]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Current concepts in the treatment of renovascular hypertension.Am J Hypertens. 2018 Jan 12; 31: 139-149
- Pharmacological effects of RAAS blockade in ischemic nephropathy.Curr Drug Metab. 2016; 17: 550-558
- Stenting and medical therapy for atherosclerotic renal-arterystenosis.N Engl J Med. 2014; 370: 13-22
- Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.Annals of internal medicine. 2009; 150 (W150-841): 840-848
- Renovascular hypertension: a unique cause of unilateral focal segmental glomerulosclerosis.Hypertens Res. 2006; 29: 203-207
- The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review.J Hypertens. 2009; 27: 1333-1340
Article info
Publication history
Published online: February 05, 2018
Accepted:
February 2,
2018
Received in revised form:
January 31,
2018
Received:
January 29,
2018
Identification
Copyright
© 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
